Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…African American patients with Parkinson’s disease: A hospital-based study compared to Caucasian patients
Objective: To characterize the demographic, socioeconomic, clinical and healthcare features of African American (AA) patients with Parkinson’s disease (PD) compared to Caucasian PD patients in…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Influence of controlled-release levodopa on quality of sleep and nocturnal movements
Objective: To evaluate the effects of controlled-released (CR) levodopa on quality of sleep and nocturnal movements as assessed with mobile health technology in patients with…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Objective: To demonstrate the adverse impact of non-medical switching on patient care. Background: Non-medical switching (NMS) is a policy under which insurers or their pharmacy…Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Therapeutic intervention of LRRK2 kinase inhibitors in Vps35 p.D620N Parkinsonism
Objective: To explore the therapeutic potential of LRRK2 kinase inhibitors in a Vps35 p.D620N mouse model of Parkinsonsim. Background: The discovery of a missense mutation, Vps35 p.D620N…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 32
- Next Page »